NYSE: TMOThermo Fisher Scientific Inc Stock
TMO Price
$512.30
Fair Value Price
N/A
Market Cap
$202.66B
52 Week Low
$250.21
52 Week High
$532.57
P/E
41.65x
P/B
6.37x
P/S
5.87x
PEG
0.67x
Dividend Yield
0.17%
Revenue
$28.50B
Earnings
$4.88B
Gross Margin
47.3%
Operating Margin
22.65%
Profit Margin
17.1%
Debt to Equity
1.01
Operating Cash Flow
$7B
Beta
0.87
Next Earnings
Feb 1, 2021
Ex-Dividend
N/A
Next Dividend
N/A
Zen Score
High
Medium
Low
52
Industry average
Reasons for this score
TMO ($512.30) is trading below its intrinsic value of $2,524.95, according to Benjamin Graham's Formula from Chapter 14 of "The Intelligent Investor"
Valuation
TMO is poor value based on its earnings relative to its share price (41.65x), compared to the US market average (40.05x)
Valuation
TMO is poor value based on its earnings relative to its share price (41.65x), compared to the US Diagnostics & Research industry average (41.13x)
Valuation
TMO News
Valuation
TMO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
41.65x
Industry
41.13x
Market
40.05x
TMO is poor value based on its earnings relative to its share price (41.65x), compared to the US market average (40.05x)
Valuation
TMO is poor value based on its earnings relative to its share price (41.65x), compared to the US Diagnostics & Research industry average (41.13x)
Valuation
TMO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.37x
Industry
7.17x
Market
36.62x
TMO is good value based on its book value relative to its share price (6.37x), compared to the US market average (36.62x)
Valuation
TMO is good value based on its book value relative to its share price (6.37x), compared to the US Diagnostics & Research industry average (7.17x)
Valuation
TMO price to earnings growth (PEG)
For valuing profitable companies with growth potential
TMO is good value based on it's Price to Earnings and rate of earnings growth, measured by PEG ratio (0.67x)
Valuation
TMO's financial health
Profit margin
Revenue
$8.5B
Net Income
$1.9B
Profit Margin
22.7%
TMO's Earnings (EBIT) of $6.45B can safely cover interest payments on company debt ($21.09B)
Financials
TMO's profit margin has increased (+2.9%) in the last year from (14.2%) to (17.1%)
Financials
Assets to liabilities
Assets
$64.1B
Liabilities
$32.2B
Debt to equity
0.66
TMO's short-term assets ($18.23B) exceed its short-term liabilities ($6.23B)
Financials
TMO's long-term liabilities ($26.01B) exceed its short-term assets ($18.23B)
Financials
TMO's debt has increased relative to shareholder equity (1.01), over the past 5 years ago (0.97)
Financials
TMO's debt to equity ratio (1.01) is considered high
Financials
Cash flow
Operating
$2.7B
Investing
-$365.0M
Financing
-$791.0M
TMO's operating cash flow ($6.86B) is sufficient to service the company's debt ($21.09B)
Financials
Thermo Fisher Scientific Stock FAQ
©2021 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
